ANN ARBOR, Mich.
Aug. 25, 2011
/PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN) announced today that it has appointed
George A. Eby
, a researcher who has conducted multiple clinical studies of zinc lozenges for the common cold, as a member of its Scientific Advisory Board.
Mr. Eby is a pioneer in the development of zinc lozenges as a treatment for the common cold. He has devoted more than 30 years to the study of zinc and is the executive director of the George Eby Research Institute. He was the first researcher to demonstrate with statistical significance that zinc lozenges can reduce the average duration of symptoms of the common cold by approximately seven days. Mr. Eby's groundbreaking placebo-controlled, randomized, double-blind clinical study was published in the
American Society for Microbiology
and is available at:
. His zinc studies have been cited in several journals, most recently in the "Zinc for the Common Cold Review" prepared by The Cochrane Collaboration® and "Zinc Lozenges May Shorten the Duration of Colds: A Systematic Review" in The Open Respiratory Medicine Journal, both published during 2011.
"I am pleased to join Adeona's Scientific Advisory Board," said
. "Adeona's zinc acetate lozenges have the potential to reduce the duration and severity of the common cold for most people. Through the development of its family of zinc-based product candidates, Adeona is uniquely positioned to introduce this new zinc lozenge for the common cold into the marketplace. I look forward to using my 30 years of zinc lozenge research to guide Adeona as it takes advantage of this large market opportunity. It is reported that consumers in the U.S. spend approximately
annually on over-the-counter treatments for the common cold, most of which I deem ineffective beyond modest symptomatic relief."
James S. Kuo
, M.D., M.B.A., Adeona's Chairman and CEO, stated, "Mr. Eby joins our Scientific Advisory Board at a very exciting time in our Company's history. We are in the process of planning the commercial launch of
, our zinc lozenge, that has been developed to reduce the duration and severity of symptoms associated with the common cold. His deep industry knowledge and vast experience in zinc research will provide us with a competitive advantage as we move forward with this program and drive corporate growth for our Company."
, Adeona acquired exclusive access to two statistically significant clinical studies that demonstrated a reduction in the duration and severity of symptoms associated with the common cold while taking a particular zinc lozenge. Based on the reduction of common cold symptoms shown in these two clinical studies conducted by
Ananda S. Prasad
, M.D., Ph.D., Adeona intends to commercialize a similar oral zinc lozenge as a homeopathic over-the-counter drug under the brand name
. Plans for manufacturing, packaging and marketing of
are currently underway.
The trademarked name,
, is derived from the combination of "well", as the product seeks to help people suffering from symptoms of the common cold, and "Zin", the root used to distinguish the family brand of zinc products under development by Adeona.
is intended to be marketed for adults in
the United States
About Adeona Pharmaceuticals' Scientific Advisory Board
Members of Adeona's Scientific Advisory Board serve on a continuing basis to advise the Company on scientific and clinical matters related to its programs, as well as recommending and reviewing business opportunities. Mr. Eby joins other industry-leading experts, including:
Ashley I. Bush
, M.D., Ph.D., a National Health and Medical Research Council Australia Fellow and Head of the Oxidation Disorders Laboratory for the Mental Health Research Institute,
University of Melbourne
Ananda S. Prasad
, M.D., Ph.D., a Distinguished Professor of Internal Medicine at
Wayne State University
School of Medicine and renowned zinc expert.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available:
™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and
™, a homeopathic over-the-counter drug for reducing symptoms associated with the common cold. Adeona also operates a wholly owned clinical reference laboratory, Adeona Clinical Laboratory, that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at
This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the commercialization of wellZin and the effectiveness of wellZin. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of wellZin to achieve desired results, a failure by us to successfully commercialize wellZin and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
SOURCE Adeona Pharmaceuticals, Inc.